Kymera Therapeutics (KYMR) Tops Q1 EPS by 7c

Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.82), $0.07 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $11.38 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MicroVision applies to transfer listing to NASDAQ capital market
• Ticketplus files for IPO with shares priced between $13-$15